News from the healthcare data industry
As real-world evidence becomes ever more essential, a cancer health technology company that played a key role in modernizing 21st-century health data is capitalizing on its accomplishments in the U.S.—and...
Jun 30, 2022 | staff reporter NEW YORK – A pan-cancer analysis involving tens of thousands of patients has spelled out new and known relationships between tumor mutations, survival outcomes, and responses...
A growing — and aging — population, combined with advances in early detection and treatment, pushed the number of cancer survivors to new heights this year. More than 18 million...
In a retrospective cohort study reported in JAMA Network Open, Sanjay Popat, FRCP, PhD, and colleagues found that among patients initiating first-line pembrolizumab for EGFR and ALK wild-type advanced non–small cell lung cancer (NSCLC), ever-smokers had...
In a study reported in a research letter in JAMA Oncology, Nimgaonkar et al found that less than half of patients with urothelial cancer who had received first-line platinum-based therapy underwent...
Teclistamab was found to have improved effectiveness in terms of progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) vs real-world physician’s choice of therapy in patients...
June 01, 2022 09:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Flatiron HealthⓇ today announced the appointment of Javier Jimenez, MD, MPH, as Chief Medical Officer, effective June 1, 2022. In his...
May 26, 2022 05:30 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical...
NEW YORK – It’s been three years since the US Food and Drug Administration agreed Janssen’s Balversa (erdafitinib) for patients with advanced bladder tumors harboring FGFR3 or FGFR2 gene alterations, however a...